Abstract:Lung cancer is presently the most commonly diagnosed metastatic tumor and the leading cause of cancer-related deaths worldwide. Moreover, drug resistance occurs frequently in lung cancer patients. There is an urgent need for developing promising anticancer drugs to improve overall survival of patients with lung cancer. In our recent antitumor drug discovery study, 1,2-di(quinazolin-4-yl)diselane (LG003) exhibited broad spectrum antitumor effects, and demonstrated such effect on A549 cells through physiological pathways rather than cytotoxicity. This suggests that compound LG003 is a potential antitumor agent. In the present study, treatment time and dosage tests indicated LG003 inhibited A549 cells in time- and dosage-dependent manner. Morphological observation did show that compound LG003 treatment resulted in inhibition of cell proliferation and morphological changes in time- and dosage-dependent manner. Subsequent cell cycle analysis revealed that LG003-induced G1-phase arrest followed by accumulation in hypodiploid population phase in cell cycle progression. The typical apoptosis-like morphological changes were also observed in synchronous observation of A549 cells. AO/EB staining and DNA ladder assay confirmed LG003-induced nuclear condensation and characteristic apoptotic DNA ladder in A549 cells. Annexin V-FITC apoptosis analysis indicated that LG003 treatment for 48 h induced the apoptosis of A549 cells in a dosage-dependent manner. Based on these results, we concluded that LG003 executed antitumor activity mainly through inhibiting cell proliferation in the early stage of treatment, then inducing apoptotic death which implied that LG003 should be a potential antitumor candidate worthing more extensive study to be developed as anticancer agents against Lung cancer.

Pioneering 4,11-Dioxo-4,11-dihydro-1<i>H</i>-anthra[2,3-<i>d</i>]imidazol-3-ium Compounds as Promising Survivin Inhibitors by Targeting ILF3/NF110 for Cancer Therapy

Pioneering 4,11-Dioxo-4,11-dihydro-1 H-anthra[2,3- d]imidazol-3-ium Compounds as Promising Survivin Inhibitors by Targeting ILF3/NF110 for Cancer Therapy

Design, Synthesis And Structure-Activity Relationship Studies Of Novel Survivin Inhibitors With Potent Anti-Proliferative Properties

A Novel Stilbene Derivative (GMQ3) Suppressed Proliferation and Induced Apoptosis in Lung Cancer Via the P38-Mapk/sirt1 Pathway

Identification of novel inhibitors of Aurora A with a 3-(pyrrolopyridin-2-yl)indazole scaffold.

Synthesis and biological evaluation of selective survivin inhibitors derived from the MX-106 hydroxyquinoline scaffold

Design, Synthesis, And Interaction Study Of Quinazoline-2(1h)-Thione Derivatives As Novel Potential Bcl-X(L) Inhibitors

Lentivirus-mediated Shrna Targeting XIAP and Survivin Inhibit SW1990 Pancreatic Cancer Cell Proliferation in Vitro and in Vivo.

Discovery and SAR Study of Quinoxaline–Arylfuran Derivatives as a New Class of Antitumor Agents

A potential anticancer agent 1,2-di(quinazolin-4-yl)diselane induces apoptosis in non-small-cell lung cancer A549 cells

Design of novel potent selective survivin inhibitors using 2D-QSAR modeling, molecular docking, molecular dynamics, and ADMET properties of new MX-106 hydroxyquinoline scaffold derivatives

A novel survivin dimerization inhibitor without a labile hydrazone linker induces spontaneous apoptosis and synergizes with docetaxel in prostate cancer cells

Design, synthesis and biological evaluation of novel potent STAT3 inhibitors based on BBI608 for cancer therapy

Synthesis, Biological Evaluation, and Molecular Docking Studies of Novel 2-Styryl-5-nitroimidazole Derivatives Containing 1,4-Benzodioxan Moiety As FAK Inhibitors with Anticancer Activity.

Design, synthesis, and biological evaluation of 6-(imidazo[1,2-a] pyridin-6-yl) quinazolin-4(3H)-one derivatives as potent anticancer agents by dual targeting Aurora kinase and ROR1

Synthesis and Evaluation of the Antitumor Activity of Novel 1-(4-Substituted phenyl)-2-ethyl Imidazole Apoptosis Inducers In Vitro

Design, synthesis, and evaluation of novel ursolic acid derivatives as HIF-1α inhibitors with anticancer potential

Discovery of an Orally Selective Inhibitor of Signal Transducer and Activator of Transcription 3 Using Advanced Multiple Ligand Simultaneous Docking

Discovery of 4-(4-(3-(1-(2-(piperidin-1-yl)ethyl)-1H-benzo[d]imidazole-2-yl)isoxazol-5-yl)phenyl)morpholine as a novel c-Myc inhibitor against lung cancer in vitro and in vivo

Synthesis and biological evaluation of novel Jiyuan Oridonin A-1,2,3-triazole-azole derivatives as antiproliferative agents.

Discovery, Optimization, and Evaluation of Novel N -(Benzimidazol-5-yl)-1,3,4-thiadiazol-2-amine Analogues as Potent STAT3 Inhibitors for Cancer Treatment